Erlotinib at a dose of 25 mg daily for non-small-cell lung cancers with EGFR mutations

PURPOSE: The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations. The usual clinical dose of gefitinib (250 mg/day) is only one third of its maximum tolerated dose (MTD), while the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yeo, Wee-Lee, Riely, Gregory J., Yeap, Beow Y., Lau, Michelle W., Warner, Jeremy L., Bodio, Kelly, Huberman, Mark S., Kris, Mark G., Tenen, Daniel G., Pao, William, Kobayashi, Susumu, Costa, Daniel B.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2893286/
https://ncbi.nlm.nih.gov/pubmed/20512075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181dd1386
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia